A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : CE / cost-effectiveness

[Related PubMed/MEDLINE]
Total Number of Papers: 196
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   CE  (>> Co-occurring Abbreviation)
Long Form:   cost-effectiveness
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 A review of the cost-effectiveness of adult influenza vaccination and other preventive services. QALY
2019 Clinical Outcomes and Cost-Effectiveness Analysis of FFR Compared with Angiography in Multivessel Disease Patient. ANGIO, FFR, MACE, NPS
2019 Cost-effectiveness analysis of newborn pulse oximetry screening to detect critical congenital heart disease in Colombia. CCHD, ICER
2019 Cost-effectiveness analysis of three algorithms for diagnosing primary ciliary dyskinesia: a simulation study. HSVM, ICE, nNO, PCD, TEM
2019 Cost-effectiveness and budgetary impact of HCV testing, treatment and linkage to care in U.S. prisons. BI, DOC, HCV, ICER, QALY, US
2019 Cost-effectiveness of Preoperative Staphylococcus aureus Screening and Decolonization in Cochlear Implantation. ARR
2019 Economic evaluation of the use of non-vitamin K oral anticoagulants in patients with atrial fibrillation on antiplatelet therapy: a modelling analysis using the healthcare system in the Netherlands. AF, APT, NOACs, QALYs, VKA
2019 Influence of Diabetes Complications on HbA1c Treatment Goals Among Older U.S. Adults: A Cost-Effectiveness Analysis. NHANES, QALY
2019 Local radiation and phototherapy are the most cost-effective treatments for stage IA mycosis fungoides: A comparative decision analysis model in the United States. LYs, MF, NB-UVB, PUVA
10  2019 Medical Doctors' Offline Computer-Assisted Digital Education: Systematic Review by the Digital Health Education Collaboration. cRCT, OCDE, RCTs, RM
11  2019 The Cost-Effectiveness of Continuous Versus Intermittent Renal Replacement Therapies in Acute Kidney Injury: Perspective of the Social Services for the Elderly in Argentina. AKI, CRRT, IRRT, RRT
12  2019 The economic impact of the transition from branded to generic oncology drugs. CCTG, CU, ICER, QALY
13  2019 Was It Worth Introducing Health Economic Evaluation of Innovative Drugs in the French Regulatory Setting? The Case of New Hepatitis C Drugs. CUA
14  2018 A cost-effectiveness analysis comparing the originator follitropin alfa to its biosimilars in patients undergoing a medically assisted reproduction program from a French perspective. MAR, NHS, OHSS, PMSI
15  2018 A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. HNCs, ICIs, NSCLC, WTP
16  2018 Cost-effectiveness and budget impact of liraglutide in type 2 diabetes patients with elevated cardiovascular risk: a US-managed care perspective. CV, CVD, MI, QALYs, SOC, T2D
17  2018 Cost-effectiveness of left ventricular assist devices for patients with end-stage heart failure: analysis of the French hospital discharge database. ICER, LVADs, QALYs
18  2018 Cost-Effectiveness Thresholds: the Past, the Present and the Future. ---
19  2018 Highly Innovative Drug Program in the Czech Republic: Description and Pharmacoeconomic Results-Cost-Effectiveness and Budget Impact Analyses. HIDs, PR, TR
20  2018 In an era of highly effective treatment, hepatitis C screening ofthe United States general population should be considered. DAA's, HCV, HRS, SA, SVR
21  2018 Measuring User Compliance and Cost Effectiveness of Safe Drinking Water Programs: A Cluster-Randomized Study of Household Ultraviolet Disinfection in Rural Mexico. HWTS, UV
22  2017 A cost-effectiveness comparison of the NICE 2015 and WHO 2013 diagnostic criteria for women with gestational diabetes with and without risk factors. GDM, HAPO, NICE, NMB, QALY
23  2017 An empirical comparison of Markov cohort modeling and discrete event simulation in a capacity-constrained health care setting. DES, DQ, ICER, MM, OPSC, QALY, UC
24  2017 Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance). SREs, ZA
25  2017 Cost-effectiveness and public health impact of alternative influenza vaccination strategies in high-risk adults. QALY, RIV, VE
26  2017 Cost-effectiveness of 'immediate IVF' versus 'delayed IVF': a prospective study. ---
27  2017 Cost-effectiveness of active case-finding of household contacts of pulmonary tuberculosis patients in a low HIV, tuberculosis-endemic urban area of Lima, Peru. ACF, DALYs, ICER, PCF, PCF, TB
28  2017 Cost-effectiveness of the 2014 U.S. Preventive Services Task Force (USPSTF) Recommendations for Intensive Behavioral Counseling Interventions for Adults With Cardiovascular Risk Factors. ICERs, IFG, NHANES, QALY, USPSTF
29  2017 Cost-effectiveness research in cancer therapy: a systematic review of literature trends, methods and the influence of funding. RCTs
30  2017 Determination of Cost-Effectiveness Threshold for Health Care Interventions in Malaysia. WTP
31  2017 Menopausal hormone therapy: a systematic review of cost-effectiveness evaluations. MHT, QOL, WHI
32  2017 Mix and match. A simulation study on the impact of mixed-treatment comparison methods on health-economic outcomes. HE, MAD, MTC
33  2016 Cost-comparativeness of proton versus photon therapy. PBT
34  2016 Cost-effectiveness of doxorubicin-eluting beads versus conventional trans-arterial chemo-embolization for hepatocellular carcinoma. cTACE, DEB-TACE, HCC, QALYs, RCTs
35  2016 Cost-effectiveness of eplerenone in NYHA class II chronic heart failure patients with reduced LVEF: an analysis for Greece. QALYs
36  2016 Cost-Effectiveness of Pharmacogenomic and Pharmacogenetic Test-Guided Personalized Therapies: A Systematic Review of the Approved Active Substances for Personalized Medicine in Germany. QHES
37  2016 Cost-effectiveness of providing patients with information on managing mild low-back symptoms in an occupational health setting. HC, LBP, PHI, SA
38  2016 Cost-effectiveness of radical hysterectomy with adjuvant radiotherapy versus radical radiotherapy for FIGO stage IIB cervical cancer. QALY
39  2016 Cost-utility of exercise therapy in patients with hip osteoarthritis in primary care. OA, QOL
40  2016 Dabigatran for the Treatment and Secondary Prevention of Venous Thromboembolism; A Cost-Effectiveness Analysis for the Netherlands. ICER, QALY, VKA, VTE
41  2016 Economic evaluation of pediatric influenza immunization program compared with other pediatric immunization programs: A systematic review. HepB, HPV, MD, PD, QALY, RV, US
42  2016 Public Health Benefits from Livestock Rift Valley Fever Control: A Simulation of Two Epidemics in Kenya. DALYs
43  2016 The effectiveness bundling of zinc with Oral Rehydration Salts (ORS) for improving adherence to acute watery diarrhea treatment in Ethiopia: cluster randomised controlled trial. ORS, pp
44  2016 The Use of Economic Evidence to Inform Drug Pricing Decisions in Jordan. ---
45  2015 A systematic review of studies eliciting willingness-to-pay per quality-adjusted life year: does it justify CE threshold? CINAHL, CRD, QALY, WHO, WTP, WTP per QALY
46  2015 Assessment of the impact of cotrimoxazole prophylaxis on key outcomes among HIV-infected adults in low- and middle-income countries: a systematic review. AIM, CTX
47  2015 Cost-effectiveness analysis of pneumococcal conjugate vaccine introduction in Paraguay. ---
48  2015 Cost-effectiveness of invitation to food supplementation early in pregnancy combined with multiple micronutrients on infant survival: analysis of data from MINIMat randomized trial, Bangladesh. IM, LY, MMS
49  2015 Cost-Effectiveness of Pazopanib Versus Sunitinib for Renal Cancer in the United States. ISPOR, mRCC, PAZ, SU
50  2015 Does age modify the cost-effectiveness of community-based physical activity interventions? PA, QALY
51  2015 Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study. BC, BEV, Cape, EVE, EXE, ICER, NSAI, Pacl, QALYs
52  2015 Impact of cotrimoxazole and insecticide-treated nets for malaria prevention on key outcomes among HIV-infected adults in low- and middle-income countries: a systematic review. CTX, ITNs, PLHIV
53  2015 Impact on total population health and societal cost, and the implication on the actual cost-effectiveness of including tumour necrosis factor-alpha antagonists in management of ankylosing spondylitis: a dynamic population modelling study. AS, NSAIDs
55  2015 Simulation models in population breast cancer screening: A systematic review. MR, RCTs
56  2015 The Cost-Effectiveness (CE) of Intravitreal Aflibercept (IVT-AFL) in the Treatment of Diabetic Macular Edema (DME) in Turkey. DME, IVT-AFL
57  2015 Valuing Trial Designs from a Pharmaceutical Perspective Using Value-Based Pricing. ENBS, VBP
58  2015 [Economic evaluation seeks threshold to support decision-making]. QALY
59  2014 A cost-effectiveness analysis of retropubic midurethral sling versus transobturator midurethral sling for female stress urinary incontinence. RMS, SUI, TMS
60  2014 A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer. KRAS, mCRC, MoAbs, QHES
61  2014 A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC). BSC, NSCLC, QHES
62  2014 Cost effectiveness of a benzodiazepine vs a nonbenzodiazepine-based sedation regimen for mechanically ventilated, critically ill adults. BZ, ICU, MV
63  2014 Cost-Effectiveness (CE) of Imaging-Guided Strategies for the Diagnosis of Coronary Artery Disease (CAD): Results From the Evinci Study. CAD
64  2014 Cost-effectiveness analysis of extended adjuvant endocrine therapy in the treatment of post-menopausal women with hormone receptor positive breast cancer. BC, Extended AI, ICERs, QALYs, SA
65  2014 Economic evaluation of enhanced asthma management: a systematic review. CB, CC, CU
66  2014 Incremental cost-effectiveness of percutaneous versus surgical closure of atrial septal defects in children under a public health system perspective in Brazil. PC, SC
67  2014 Not simply more of the same: distinguishing between patient heterogeneity and parameter uncertainty. COPD, ICER, PSA
68  2014 Outcome impact and cost-effectiveness of quality assurance for radiotherapy planned for the EORTC 22071-24071 prospective study for head and neck cancer. ICRs, QALYs, QART
69  2013 A choice that matters? Smulation study on the impact of direct meta-analysis methods on health economic outcomes. BFE, bias, FFE, HE
70  2013 Cost-effectiveness acceptability curves revisited. CEAC, ICERs
71  2013 Cost-effectiveness analysis of tension-free vaginal tape vs burch colposuspension for female stress urinary incontinence in the USA. BC, QALY, SUI, TVT
72  2013 Cost-effectiveness of a hypertension control intervention in three community health centers in China. DBP, RMB, SBP
73  2013 Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. HCC, RFA
74  2013 Cost-Effectiveness of Surgical Treatment for Adult Spinal Deformity: A Comparison of Dollars per Quality of Life Improvement Across Health Domains. ASD, HRQoL, ODI, PCS, SRS
75  2013 Cost-effectiveness of the School-Based Asthma Therapy (SBAT) program. SBAT, SFDs, UC
76  2013 Costo-Efectividad de la Proteina C Reactiva, Procalcitonina y Escala de Rochester: Tres Estrategias Diagnosticas para la Identificacion de Infeccion Bacteriana Severa en Lactantes Febriles sin Foco. SBI
77  2013 Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation. AF, ICER, QALYs, SA
78  2013 Endogenous cost-effectiveness analysis and health care technology adoption. ---
79  2013 Health Economics Information in Wound Care: The Elephant in the Room. HE, ICERs
80  2013 Mental health economics: insights from Brazil. HTA
81  2013 The road not taken: transferability issues in multinational trials. QALYs, RCTs
82  2013 The role of value-of-information analysis in a health care research priority setting: a theoretical case study. EVPPI, PSA
83  2013 Zinc and copper supplementation are not cost-effective interventions in the treatment of acute diarrhea. PL, Zn
84  2012 A direct method and ICER tables for the estimation of the cost-effectiveness of smoking cessation interventions in general populations: application to a new cytisine trial and other examples. ICERs
85  2012 Cost effectiveness of concurrent gemcitabine and cisplatin with radiation followed by adjuvant gemcitabine and cisplatin in patients with stages IIB to IVA carcinoma of the cervix. ICER, OS, PFS, QALY, QOL, SA
86  2012 Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care. QALYs
87  2012 Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population. HCC, ICER, ITA.LI.CA, QALMs
88  2012 Head-to-head comparison of the 70-gene signature versus the 21-gene assay: cost-effectiveness and the effect of compliance. AO, LYs, QALYs, SG
89  2012 Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis. CDM, ICERs
90  2012 Worksite mental health interventions: a systematic review of economic evaluations. CHEC-list, RTW
91  2012 [Cost-effectiveness of tumor necrosis factor in Crohn's disease]. CD, TNF
92  2011 A dynamic perspective on pharmaceutical competition, drug development and cost effectiveness. ---
93  2011 An incremental economic evaluation of targeted and universal influenza vaccination in pregnant women. FP, PHC
94  2011 Cost effectiveness of pediatric pneumococcal conjugate vaccines: a comparative assessment of decision-making tools. PAHO, PCV, WHO
95  2011 Cost-effectiveness analysis for Pap smear screening and human papillomavirus DNA testing and vaccination. HPV
96  2011 Cost-effectiveness and accuracy of prenatal Down syndrome screening strategies: should the combined test continue to be widely used? DS
97  2011 Largely ignored: the impact of the threshold value for a QALY on the importance of a transferability factor. INMB, SCS, WTP
98  2011 Overview of methods in economic analyses of behavioral interventions to promote oral health. ---
99  2011 Rapid testing versus karyotyping in Down's syndrome screening: cost-effectiveness and detection of clinically significant chromosome abnormalities. CA, DS, DSSP, FISH, ICER, QF-PCR, RAD
100  2011 Reducing surface water pollution through the assessment of the cost-effectiveness of BMPs at different spatial scales. BMPs, HRU, NPS, SWAT, TP